Is NCT04853251 recruiting in Bakersfield, CA?

Yes, NCT04853251 is currently recruiting participants at its Bakersfield, CA location. This macular degeneration clinical trial is actively enrolling qualified participants.

How do I join the macular degeneration clinical trial in Bakersfield?

To join this clinical trial in Bakersfield, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bakersfield clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Macular Degeneration Clinical Trial in Bakersfield, CA

Who Can Participate

Inclusion Criteria

Ocular Inclusion Criteria:

Diagnosis of nAMD prior to screening as determined by the investigator

Difference of \<10% in ECD at screening between the 2 eyes as measured by specular microscopy and determined by the independent reading center

Availability of historical visual acuity (VA) data and spectral-domain optical coherence tomography (SD-OCT). Additionally, fluorescein angiography or color fundus photography can both be used to support participant eligibility per protocol at investigator discretion

Availability of comprehensive historical anti-vascular endothelial growth factor (VEGF) injection data, including agent administered and date of administration from the time of diagnosis, or for at least 2 years prior to screening if diagnosis was made more than 2 years before screening

Response to at least two prior anti-VEGF IVT injections as determined by the investigator based on the following:

Overall decrease in nAMD disease activity detected on historical or screening OCT

Stable or improved best-corrected visual acuity (BCVA)

BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better, using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters at screening and enrollment

All subtypes of nAMD lesions are permissible

nAMD lesions at the time of diagnosis must involve the macula

Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical examination and analysis and grading by the central reading center of SD-OCT images

Exclusion Criteria

Prior Ocular Treatment Study Eye:

Prior treatment with external-beam radiation therapy or transpupillary thermotherapy

Previous treatment with verteporfin injection (PDT) or corticosteroid IVT injection within 2 years of screening

Previous laser (except PDT as stated above) used for age related macular degeneration (AMD) treatment

History of corneal transplant

History of conjunctival surgery in the superotemporal quadrant

History of intraocular inflammation following anti-VEGF injection Either Eye:

Previous PDS implantation

Previous intraocular surgery (including cataract surgery) within 6 months of study enrollment

Prior vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD)

Prior pars plana vitrectomy surgery

Previous intraocular device implantation, excluding intraocular lenses

History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery

Prior participation in a clinical trial involving any intravitreal agents that are not approved at time of screening

Intraocular laser therapy, including selective laser trabeculoplasty, yttrium-aluminum garnet (YAG), prophylactic peripheral iridotomy within 1 year of screening, or YAG capsulotomy within 3 months of screening

Contact lens wear in either eye within 2 months of screening

Any prior penetrating ocular trauma

Any prior ocular blunt trauma affecting corneal or retinal health in the opinion of the investigator, or any ocular blunt trauma within 6 months of screening

History of corneal transplantation, including partial-thickness corneal grafts

Prior treatment with brolucizumab

Prior treatment with external-beam radiation therapy or brachytherapy

History of hypersensitivity to ranibizumab or any excipients of Susvimo Macular Neovascularization Lesion (MNV) Characteristics Study Eye:

Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5-disc area \[1.27 square millimeters (mm\^2)\] in size

Subfoveal fibrosis or subfoveal atrophy Either Eye:

MNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia

MNV masquerading lesions (e.g., cone dystrophy, adult vitelliform dystrophy, pattern dystrophy) Current or Historical Ocular Conditions Study Eye:

Retinal pigment epithelial tear

Retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated, or treated within the 3 months prior to study enrollment

Current vitreous hemorrhage

Current or history of retinal detachment

Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation

Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia or evidence of pathologic myopia on depressed fundus examination

Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery

Spherical equivalent of the refractive error demonstrating more than 5 diopters of hyperopia

Preoperative refractive error that exceeds 5 diopters of hyperopia, for participants who have undergone prior refractive or cataract surgery

Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study

Scleral pathology in the superotemporal quadrant (e.g., scleral thinning or calcification)

Conjunctival pathologies in the superotemporal quadrant

History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis

Ectropion, entropion or other impairment of the upper or lower eyelid impacting lid functionality needed to protect the ocular surface from exposure

Corneal neuropathy

Lagophthalmos or incomplete blink

Active or history of facial nerve palsy/paresis Fellow (Non-Study) Eye: • Concurrent or history of PDS implantation Either Eye:

Aphakia or absence of the posterior capsule

Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results

Corneal ECD ≤1500 cells/mm2 in either eye at screening as determined by the independent reading center

Fuchs endothelial corneal dystrophy Grade ≥ 2

Previous corneal endothelial cell damage, including from blunt or surgical trauma

Any ocular condition that precludes obtaining an analyzable specular microscopy image

Active or history of corneal edema

Active or history of corneal dystrophies

Active or history of iridocorneal endothelial syndrome

Active or history of pseudoexfoliation syndrome

Active or history of herpetic keratitis or kerato-uveitis

Any active or history of uveitis

Active intraocular inflammation

Active or history of keratitis, scleritis, or endophthalmitis

Active ocular or periocular infection

Active or history of Sjogren's syndrome or keratoconjunctivitis sicca

Active or history of floppy eyelid syndrome

Active or history of chronic eye rubbing

Active thyroid eye disease Concurrent Systemic Conditions:

History of uncontrolled blood pressure

Active or history of autoimmune diseases such as rheumatoid arthritis, lupus, granulomatosis with polyangiitis (Wegener's)

History of stroke within the last 3 months prior to screening

Uncontrolled atrial fibrillation within 3 months of screening

History of myocardial infarction within the last 3 months prior to screening

History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the patient at high risk of treatment complications, in the opinion of the investigator

Current active systemic infection

Use of any systemic anti-VEGF agents

Chronic use of oral corticosteroids

Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤ 6 and a stable prostate-specific antigen for \> 12 months

Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month prior to screening (excluding vitamins and minerals)

Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the screening visit

Requirement for continuous use of any medications or treatments indicated as prohibited therapy

Pregnant or breastfeeding, or intention to become pregnant during the study

Women of childbearing potential must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bakersfield?

Yes, this clinical trial (NCT04853251) has an active research site in Bakersfield, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Macular Degeneration Treatment Options in Bakersfield, CA

If you're searching for macular degeneration treatment options in Bakersfield, CA, this clinical trial (NCT04853251) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bakersfield research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all macular degeneration clinical trials near you to find additional studies recruiting in your area.

Macular Degeneration Clinical Trial in Bakersfield, CA

Expert Care in Bakersfield

IRB Approved

No-Cost Care

Apply for This Bakersfield Location

Why Participate?

Simple Process

About This Macular Degeneration Study in Bakersfield